Natixis Advisors’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Natixis Advisors’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-46,103	Closed	-$2.49M	–	1097
2017 Q4	$2.49M	Buy	46,103 +5,550	+14%	+$304K	0.03%	653
2017 Q3	$2.31M	Sell	40,553 -402	-1%	-$23.5K	0.02%	685
2017 Q2	$2.46M	Buy	40,955 +16,231	+66%	+$924K	0.03%	644
2017 Q1	$1.35M	Buy	+24,724	New	+$1.22M	0.01%	797

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Natixis Advisors's BIVV Position: Q1 2018 in Review

Natixis Advisors sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 46,103 shares — an estimated $2.49M sold.

Natixis Advisors first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $2.49M in Q4 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

Natixis Advisors reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Natixis Advisors sold 46,103 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $2.49M.
Natixis Advisors first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
Natixis Advisors's Bioverativ Inc. Common Stock position peaked at $2.49M in Q4 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Natixis Advisors's 13F filing for Q1 2018, filed 10 May 2018.